Solventum Corporation (NYSE:SOLV) Stock Has Consensus Price Target of $92.80 According to Analysts

Solventum Corporation (NYSE:SOLV) has been given an average recommendation of “Moderate Buy” by the fourteen ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $92.80.

Several research analysts have recently weighed in on SOLV shares. Stifel Nicolaus increased their price target on Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Mizuho set a $113.00 price objective on Solventum in a research note on Thursday, August 6th. Wedbush upped their price objective on shares of Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. BMO Capital Markets assumed coverage on shares of Solventum in a research report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 target price for the company. Finally, BTIG Research reiterated a “buy” rating and issued a $95.00 target price on shares of Solventum in a research note on Monday, September 14th.

Solventum Stock Up 0.6%

Solventum stock opened at $85.91 on Thursday. The firm has a 50 day moving average price of $88.60 and a 200-day moving average price of $78.56. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. Solventum has a twelve month low of $62.38 and a twelve month high of $94.16. The company has a market capitalization of $14.62 billion, a P/E ratio of 12.03, a P/E/G ratio of 1.31 and a beta of 0.63.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%. The business had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.15 billion. During the same period in the prior year, the company earned $1.69 earnings per share. Solventum’s revenue was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, equities analysts predict that Solventum will post 7.22 EPS for the current year.

Institutional Trading of Solventum

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Park Avenue Securities LLC increased its holdings in Solventum by 13.2% during the 3rd quarter. Park Avenue Securities LLC now owns 3,593 shares of the company’s stock worth $317,000 after acquiring an additional 420 shares during the period. Apollon Wealth Management LLC raised its holdings in shares of Solventum by 14.8% in the 3rd quarter. Apollon Wealth Management LLC now owns 4,786 shares of the company’s stock valued at $422,000 after acquiring an additional 616 shares in the last quarter. Sigma Planning Corp bought a new stake in shares of Solventum during the 3rd quarter valued at about $231,000. Signaturefd LLC boosted its position in shares of Solventum by 51.8% during the 3rd quarter. Signaturefd LLC now owns 2,119 shares of the company’s stock valued at $187,000 after acquiring an additional 723 shares during the last quarter. Finally, Citizens Financial Group Inc. RI grew its holdings in shares of Solventum by 111.9% during the third quarter. Citizens Financial Group Inc. RI now owns 6,342 shares of the company’s stock worth $559,000 after purchasing an additional 3,349 shares in the last quarter.

About Solventum

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.